Tecemotide in unresectable stage III non-small-cell lung cancer in the phase III START study: Updated overall survival and biomarker analyses

Annals of Oncology

Volumn 26, Issue 6, 2015, Pages 1134-1142

  Mitchell, Paul L ^a   Thatcher, N ^b   Socinski, M A ^c   Wasilewska Tesluk, E ^d   Horwood, K ^e   Szczesna, A ^f   Martin C ^g   Ragulin, Y ^h   Zukin, M ⁱ   Helwig, C ^j   Falk, M ^j   Butts, C ^k   Shepherd, F A ^l  

^a AUSTIN HOSPITAL   (Australia)

^b CHRISTIE HOSPITAL   (United Kingdom)

^c UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^d UNIVERSITY OF WARMIA AND MAZURY IN OLSZTYN   (Poland)

^e PRINCESS ALEXANDRA HOSPITAL   (Australia)

^f Division III   (Poland)

^g Instituto Especializado Alexander Fleming   (Argentina)

^h MEDICAL RADIOLOGICAL RESEARCH CENTER   (Russian Federation)

ⁱ INSTITUTO NACIONAL DE CÂNCER   (Brazil)

^j MERCK KGAA   (Germany)

^k CROSS CANCER INSTITUTE   (Canada)

^l PRINCESS MARGARET HOSPITAL   (Canada)

more..

Author keywords

ANA; MUC1; Soluble MUC1; Tecemotide

Indexed keywords

ANTINUCLEAR ANTIBODY; MUCIN 1; PLACEBO; TECEMOTIDE; CANCER VACCINE; L-BLP25; MEMBRANE PROTEIN; MUC1 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER STAGING; CHEMORADIOTHERAPY; FEMALE; FOLLOW UP; HLA SYSTEM; HUMAN; LYMPHOCYTE; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; NEUTROPHIL; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; VERY ELDERLY; ADJUVANT CHEMORADIOTHERAPY; BLOOD; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIAL; CONTROLLED STUDY; IMMUNOLOGY; KAPLAN MEIER METHOD; LUNG NEOPLASMS; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PATHOLOGY; PHASE 3 CLINICAL TRIAL; PREDICTIVE VALUE; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; TIME FACTOR; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, ANTINUCLEAR; BIOMARKERS, TUMOR; CANCER VACCINES; CARCINOMA, NON-SMALL-CELL LUNG; CHEMORADIOTHERAPY, ADJUVANT; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; LYMPHOCYTE COUNT; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; MUCIN-1; NEUTROPHILS; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84938077149     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdv104     Document Type: Article

References (22)

1. Auperin A, Le Pechoux C, Rolland E et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol 2010; 28: 2181-2190.
2. Tsujino K, Kurata T, Yamamoto S et al. Is consolidation chemotherapy after concurrent chemo-radiotherapy beneficial for patients with locally advanced nonsmall- cell lung cancer? A pooled analysis of the literature. J Thorac Oncol 2013; 8: 1181-1189.
3. Butts C, Socinski MA, Mitchell PL et al. Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial. Lancet Oncol 2014; 15: 59-68.
4. Acres B, Limacher JM. MUC1 as a target antigen for cancer immunotherapy. Expert Rev Vaccines 2005; 4: 493-502.
5. Giatromanolaki A, Koukourakis MI, Sivridis E et al. Coexpression of MUC1 glycoprotein with multiple angiogenic factors in non-small cell lung cancer suggests coactivation of angiogenic and migration pathways. Clin Cancer Res 2000; 6: 1917-1921.
6. Situ D, Wang J, Ma Y et al. Expression and prognostic relevance of MUC1 in stage IB non-small cell lung cancer. Med Oncol 2011; 28(Suppl 1): S596-S604.
7. Mitchell PL, Battye S, John T et al. Expression of Mucin 1 in non-small cell lung cancer: Relationship between immunohistochemistry, tumor characteristics and survival. WCLC abstract 2765. J Thorac.Oncol 2013; 8(Suppl 2): S1091-S1092.
8. Treon SP, Maimonis P, Bua D et al. Elevated soluble MUC1 levels and decreased anti-MUC1 antibody levels in patients with multiple myeloma. Blood 2000; 96:3147-3153.
9. Agrawal B, Gendler SJ, Longenecker BM. The biological role of mucins in cellular interactions and immune regulation: prospects for cancer immunotherapy. Mol Med Today 1998; 4: 397-403.
10. Imai H, Ochs RL, Kiyosawa K et al. Nucleolar antigens and autoantibodies in hepatocellular carcinoma and other malignancies. Am J Pathol 1992; 140:859-870.
11. Blaes F, Klotz M, Huwer H et al. Antineural and antinuclear autoantibodies are of prognostic relevance in non-small cell lung cancer. Ann Thorac Surg 2000; 69:254-258.
12. Yao Y, Yuan D, Liu H et al. Pretreatment neutrophil to lymphocyte ratio is associated with response to therapy and prognosis of advanced non-small cell lung cancer patients treated with first-line platinum-based chemotherapy. Cancer Immunol Immunother 2013; 62: 471-479.
13. Tomita M, Shimizu T, Ayabe T et al. Preoperative neutrophil to lymphocyte ratio as a prognostic predictor after curative resection for non-small cell lung cancer. Anticancer Res 2011; 31: 2995-2998.
14. Kobayashi N, Usui S, Kikuchi S et al. Preoperative lymphocyte count is an independent prognostic factor in node-negative non-small cell lung cancer. Lung Cancer 2012; 75: 223-227.
15. Butts C, Maksymiuk A, Goss G et al. Updated survival analysis in patients with stage IIIB or IV non-small-cell lung cancer receiving BLP25 liposome vaccine (L-BLP25): phase IIB randomized, multicenter, open-label trial. J Cancer Res Clin Oncol 2011; 137: 1337-1342.
16. Ishikawa N, Hattori N, Yokoyama A et al. Usefulness of monitoring the circulating Krebs von den Lungen-6 levels to predict the clinical outcome of patients with advanced nonsmall cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors. Int J Cancer 2008; 122: 2612-2620.
17. Tanaka S, Hattori N, Ishikawa N et al. Krebs von den Lungen-6 (KL-6) is a prognostic biomarker in patients with surgically resected nonsmall cell lung cancer. Int J Cancer 2012; 130: 377-387.
18. Kohno N, Akiyama M, Kyoizumi S et al. Detection of soluble tumor-associated antigens in sera and effusions using novel monoclonal antibodies, KL-3 and KL-6, against lung adenocarcinoma. Jpn J Clin Oncol 1988; 18: 203-216.
19. Agrawal B, Krantz MJ, Reddish MA et al. Cancer-associated MUC1 mucin inhibits human T-cell proliferation, which is reversible by IL-2. Nat Med 1998; 4: 43-49.
20. Chan AK, Lockhart DC, von Bernstorff W et al. Soluble MUC1 secreted by human epithelial cancer cells mediates immune suppression by blocking T-cell activation. Int J Cancer 1999; 82: 721-726.
21. Wurz GT, Gutierrez AM, Greenberg BE et al. Antitumor effects of L-BLP25 Antigenspecific tumor immunotherapy in a novel human MUC1 transgenic lung cancer mouse model. J Transl Med 2013; 11: 64.
22. Mitchell PL, Asadi K, John T et al. Mucin 1 (MUC1) expression in patients with early stage non-small cell lung cancer; relationship between immunohistochemistry in primary tumour and plasma soluble MUC1 (sMUC1) level. J.Thorac.Oncol 2014; 9 (Suppl 1): S25 (Abstract 57P).